Biotech Firm Makes Historic Pivot into Digital Assets
Tharimmune, Inc., once known for developing treatments for rare immune and oncologic diseases, has made a striking move. The company has raised 540 million in a private placement to fund a new digital asset treasury strategy centred on Canton Coin.
The raise was led by DRW and Liberty City Ventures. Other major participants included ARK Invest, Kraken, Polychain Capital, Tradeweb Markets, and SBI Group.
The Canton Foundation, which governs the Canton Network, also joined the round. That makes Tharimmune the first publicly traded company to receive direct support from the foundation.
